Glossary · Conditions

Breast cancer survivors and menopause

Definition: Breast cancer survivors, particularly those with HR-positive disease, often have severe menopausal symptoms — partly from chemotherapy-induced or natural menopause and partly from endocrine therapy (tamoxifen, aromatase inhibitors). Treatment options include non-hormonal medications, low-dose vaginal estrogen with oncology team input, and lifestyle measures.

Detailed definition

Breast cancer survivors face menopausal symptoms from multiple sources: chemotherapy-induced ovarian failure, surgical menopause (in BRCA carriers undergoing risk-reducing BSO), and the symptom-amplifying effects of endocrine therapy with tamoxifen or aromatase inhibitors. Approximately 70–80% of breast cancer survivors on endocrine therapy report significant vasomotor symptoms, and GSM is nearly universal. Systemic estrogen is generally contraindicated in HR-positive breast cancer survivors. Options include: fezolinetant for vasomotor symptoms (relatively new but well-suited mechanistically); SSRIs/SNRIs (avoid paroxetine and fluoxetine in tamoxifen patients due to CYP2D6 inhibition; venlafaxine is preferred); gabapentin for nighttime hot flashes; vaginal moisturizers and lubricants; intravaginal DHEA (prasterone); ospemifene; and low-dose vaginal estrogen with explicit oncology team input. Low-dose vaginal estrogen has not been associated with breast cancer recurrence in available studies and is increasingly considered acceptable for severe GSM with informed consent.

Why it matters in menopause

Breast cancer survivors deserve aggressive symptom management — they have often endured years of severe quality-of-life impact under the assumption that no treatment was safe. Fezolinetant, vaginal DHEA, ospemifene, and (with oncology consultation) low-dose vaginal estrogen materially expand options.

Sources

External references: Wikipedia.

← Back to full glossary